Morgan Stanley Akero Therapeutics, Inc. Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 471,535 shares of AKRO stock, worth $23.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

471,535

Previous 448,070 5.24%

Holding current value

$23.2 Million

Previous $12.9 Million 2.05%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$26.75 - $35.28 $627,688 - $827,845	23,465 Added 5.24%	471,535 $13.1 Million
Q3 2024 Nov 14, 2024	SELL	$21.45 - $29.34 $10.7 Million - $14.6 Million	-498,458 Reduced 52.66%	448,070 $12.9 Million
Q2 2024 Oct 17, 2024	BUY	$18.31 - $24.62 $9.94 Million - $13.4 Million	542,665 Added 134.37%	946,528 $22.2 Million
Q2 2024 Aug 14, 2024	BUY	$18.31 - $24.62 $9.94 Million - $13.4 Million	542,665 Added 134.37%	946,528 $22.2 Million
Q1 2024 Oct 17, 2024	SELL	$17.76 - $31.18 $9.64 Million - $16.9 Million	-542,665 Reduced 57.33%	403,863 $10.2 Million
Q1 2024 Aug 16, 2024	SELL	$17.76 - $31.18 $11.6 Million - $20.4 Million	-653,464 Reduced 61.8%	403,863 $10.2 Million
Q1 2024 May 15, 2024	SELL	$17.76 - $31.18 $11.6 Million - $20.4 Million	-653,464 Reduced 61.8%	403,863 $10.2 Million
Q4 2023 Aug 16, 2024	BUY	$11.38 - $50.33 $1.26 Million - $5.58 Million	110,799 Added 11.71%	1,057,327 $24.7 Million
Q4 2023 Feb 13, 2024	BUY	$11.38 - $50.33 $7.03 Million - $31.1 Million	617,591 Added 140.45%	1,057,327 $24.7 Million
Q3 2023 Nov 15, 2023	BUY	$41.19 - $52.25 $2.23 Million - $2.83 Million	54,078 Added 14.02%	439,736 $22.2 Million
Q2 2023 Aug 14, 2023	BUY	$36.89 - $56.88 $1.04 Million - $1.6 Million	28,065 Added 7.85%	385,658 $18 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $50.24 $5.61 Million - $7.57 Million	150,593 Added 72.75%	357,593 $13.7 Million
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $459,699 - $753,335	13,747 Added 7.11%	207,000 $11.3 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $548,607 - $1.84 Million	54,050 Added 38.83%	193,253 $6.58 Million
Q2 2022 Oct 27, 2022	SELL	$8.0 - $15.01 $222,784 - $417,998	-27,848 Reduced 16.67%	139,203 $1.32 Million
Q2 2022 Aug 15, 2022	SELL	$8.0 - $15.01 $222,784 - $417,998	-27,848 Reduced 16.67%	139,203 $1.32 Million
Q1 2022 Oct 27, 2022	BUY	$12.97 - $22.26 $361,188 - $619,896	27,848 Added 20.01%	167,051 $2.37 Million
Q1 2022 May 13, 2022	BUY	$12.97 - $22.26 $1.27 Million - $2.17 Million	97,627 Added 140.62%	167,051 $2.37 Million
Q4 2021 Feb 14, 2022	BUY	$19.87 - $26.24 $241,917 - $319,472	12,175 Added 21.27%	69,424 $1.47 Million
Q3 2021 Nov 15, 2021	BUY	$18.65 - $25.46 $1.07 Million - $1.46 Million	57,249 New	57,249 $1.28 Million

Others Institutions Holding AKRO

# of Institutions

210

Shares Held

74.3M

Call Options Held

321K

Put Options Held

558K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.28B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account